The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 19, 2011
Filed:
Oct. 30, 2002
Jan Izdebski, Warszawa, PL;
Danuta Kunce, Warszawa, PL;
Alicja Orlowska, Warszawa, PL;
Ewa Witkowska, Warszawa, PL;
Wieslaw Szelejewski, Warszawa, PL;
Andrzej Kutner, Warszawa, PL;
Krzysztof Bankowski, Warszawa, PL;
Elzbieta Frackiewicz, Warszawa, PL;
Jan Izdebski, Warszawa, PL;
Danuta Kunce, Warszawa, PL;
Alicja Orlowska, Warszawa, PL;
Ewa Witkowska, Warszawa, PL;
Wieslaw Szelejewski, Warszawa, PL;
Andrzej Kutner, Warszawa, PL;
Krzysztof Bankowski, Warszawa, PL;
Elzbieta Frackiewicz, Warszawa, PL;
Instytut Farmaceutyczny, Warszawa, PL;
Zaklady Farmaceutyczne Polpharma, Starogard Gdanski, PL;
Abstract
Growth hormone-releasing hormone analogs having the amino acid sequence of the formula: Dat-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-R-R-VAL-Leu-Ala-Gln-Leu-Ser-Ala-R-R-Leu-Leu-Gln-Asp-Ile-Nle-Asp-R-NH(I), wherein Ris hArg, Gab or Gap; Ris hArg, Orn, Gab or Gap; Ris hArg, hArg, Gab or Gap; Ris hArg, Orn, Gab or Gap; Ris D-Arg, hArg, Gab or Gap; and their pharmaceutically acceptable salts. Said peptides are potent and selective stimulators of GH release and they are highly resistant to enzymatic degradation. Said peptides are prepared using the solid phase synthesis method, by introducing suitable derivatives of lysine, 2,4-diaminobutyric acid or 2,3-diaminopropionic acid at appropriate positions in the peptide chain attached to a polymeric support, deprotecting side-chain amino groups and reacting free amino groups with a guanidinating agent, removing all remaining t-butyloxycarbonyl protective groups, and cleaving the synthesized peptide from the support, followed by purification and optionally, converting the peptide into a pharmaceutically acceptable salt.